HERON THERAPEUTICS, INC. /DE/
Close on Oct 19, 2026
- Market cap
- $68.69M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | Before market open | $37.70M | $-0.03 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | Before market open | $34.70M | $-0.04 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $40.59M | $-0.02 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | Before market open | $38.20M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 8, 2025 | Before market open | $37.20M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | Before market open | $38.90M | $0.01 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | $32.81M | $-0.03 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 12, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on May 11, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | 2026 Full-Year | $10.00M to $20.00M | Maintained |
| Net RevenueGAAP | 2026 Full-Year | $173.00M to $183.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Heron Therapeutics filed with the SEC
Heron Therapeutics Announces Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
U.S. District Court Issues Decision Regarding CINVANTI ® Patents
Other events · EX-99.1 to Form 8-K
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
Results of operations · EX-99.1 to Form 8-K
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue;
Regulation FD disclosure · EX-99.1 to Form 8-K
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
Results of operations · EX-99.1 to Form 8-K
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
Material agreement · Results of operations · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
Material agreement · Results of operations · New financial obligation · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI ® and APONVIE ® Patent Litigations
Other events · EX-99.1 to Form 8-K
Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
Regulation FD disclosure · EX-99.1 to Form 8-K
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF ® Vial Access Needle (“VAN”)
Regulation FD disclosure · EX-99.1 to Form 8-K
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF ® Vial Access Needle (“VAN”)
Regulation FD disclosure · EX-99.1 to Form 8-K
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Heron Therapeutics Announces FDA Approval of ZYNRELEF ® Indication Expansion to
Other events · EX-99.1 to Form 8-K
Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Heron Therapeutics Announces $30 Million Private Placement Financing
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Heron Therapeutics Announces Cost Reduction Plan and Restructuring
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates
Results of operations · EX-99 to Form 8-K
Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Heron Therapeutics Announces U.S. FDA Approval of APONVIE TM (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV)
Other events · EX-99.1 to Form 8-K
APONVIE™ (HTX-019) FDA Approval September 19, 2022 Exhibit 99.2
Other events · EX-99.2 to Form 8-K
Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates
Results of operations · EX-99.1 to Form 8-K